Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly
Co-Founded By Former Impact Biomedicines CEO, Initial Focus Is IPF
John Hood spent the past few years looking for a drug candidate worth forming a new company around before he zeroed in on Lilly’s taladegib as a treatment for idiopathic pulmonary fibrosis.
